Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 4, 2026

Regeneron and CytomX extend cancer therapy partnership to $4bn deal

Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies, with the deal’s total potential value rising to up to $4bn.

CytomX will receive a $37m payment for two targets, with Regeneron able to select six additional targets. Credit: viewimage / Shutterstock.com.